<?xml version="1.0" encoding="UTF-8"?>
<Pathway xmlns="http://pathvisio.org/GPML/2013a" Name="Loss of Function of SMAD2/3 in Cancer" Organism="Homo sapiens">
  <Comment Source="WikiPathways-description">Loss-of-function of SMAD2 and SMAD3 in cancer occurs less frequently than the loss of SMAD4 function and was studied in most detail in colorectal cancer (Fleming et al. 2013).&lt;br&gt;&lt;br&gt;Similarly to SMAD4, coding sequence mutations in SMAD2 and SMAD3 in cancer cluster in the MH2 domain, involved in the formation of transcriptionally active heterotrimers with SMAD4. Another region of SMAD2 and SMAD3 that is frequently mutated in cancer is the phosphorylation motif Ser-Ser-X-Ser at the very C-terminus (Fleming et al. 2013). The phosphorylation of this conserved motif by the activated TGF-beta receptor complex is an essential step in SMAD2 and SMAD3 activation and a prerequisite for the formation of heterotrimers with SMAD4 (Chacko et al. 2001, Chacko et al. 2004).&lt;br&gt;&lt;br&gt;Smad2 knockout mice die at embryonic day 8.5, with impaired visceral endoderm function and deficiency in mesoderm formation. Smad2+/- heterozygotes appear normal and are fertile (Hamamoto et al. 2002). While polyps of compound Smad2+/-;Apc+/- mice show no difference in the number, size or histopathology from the polyps of Apc+/- mice (Takaku et al. 2002, Hamamoto et al. 2002), Smad2+/-;Apc+/- mice develop extremely large intestinal tumors and multiple invasive cancers not observed in Apc+/- mice. Therefore, loss of Smad2 does not contribute to initiation of intestinal tumorigenesis, but accelerates malignant progression (Hamamoto et al. 2002). Smad3 knockout mice are viable and fertile but die between 4 and 6 months of age from colorectal adenocarcinoma (Zhu et al. 1998), indicating that the loss of Smad3 initiates intestinal tumorigenesis.
 View original pathway at [http://www.reactome.org/PathwayBrowser/#DIAGRAM=3304349 Reactome].</Comment>
  <Comment Source="Reactome-Converter">Pathway is converted from Reactome ID: 3304349</Comment>
  <Comment Source="Reactome-version">Reactome version: 88</Comment>
  <Comment Source="Reactome Author">Reactome Author: Meyer, Dominique</Comment>
  <BiopaxRef>bb8</BiopaxRef>
  <BiopaxRef>f8a</BiopaxRef>
  <BiopaxRef>b5f</BiopaxRef>
  <BiopaxRef>c0c</BiopaxRef>
  <BiopaxRef>dc2</BiopaxRef>
  <BiopaxRef>f50</BiopaxRef>
  <Attribute Key="reactome_id" Value="3304349" />
  <Graphics BoardWidth="364.0" BoardHeight="171.0" />
  <DataNode TextLabel="SMAD2/3 MH2 Domain&#xA;Mutants in Cancer" GraphId="de810" Type="Pathway">
    <Comment Source="Reactome">Mutations in the MH2 domain of SMAD2 and SMAD3 affect their ability to form heterotrimers with SMAD4, thereby impairing TGF-beta signaling (Fleming et al. 2013).&lt;br&gt;&lt;br&gt;The SMAD2 and SMAD3 MH2 domain residues most frequently targeted by missense mutations are those that are homologous to SMAD4 MH2 domain residues shown to be involved in the formation of SMAD heterotrimers. Asp300 of SMAD2 and Asp258 of SMAD3 correspond to the frequently mutated Asp351 of SMAD4. Pro305 of SMAD2 corresponds to the frequently mutated Pro356 of SMAD4, while Ala354 of SMAD2 corresponds to Ala406 of SMAD4. Arg268 of SMAD3 corresponds to the frequently mutated Arg361 of SMAD4. SMAD2 and SMAD3 MH2 domain mutations have been examined in most detail in colorectal cancer (Fleming et al. 2013).</Comment>
    <BiopaxRef>bb8</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="174.5" CenterY="44.5" Width="315.0" Height="57.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-3315487" />
  </DataNode>
  <DataNode TextLabel="SMAD2/3&#xA;Phosphorylation&#xA;Motif Mutants in&#xA;Cancer" GraphId="a4c42" Type="Pathway">
    <Comment Source="Reactome">The conserved phosphorylation motif Ser-Ser-X-Ser at the C-terminus of SMAD2 and SMAD3 is subject to disruptive mutations in cancer. The last two serine residues in this conserved motif, namely Ser465 and Ser467 in SMAD2 and Ser423 and Ser425 in SMAD3, are phosphorylated by the activated TGF beta receptor complex (Macias Silva et al. 1996, Nakao et al. 1997). Once phosphorylated, SMAD2 and SMAD3 form transcriptionally active heterotrimers with SMAD4 (Chacko et al. 2001, Chacko et al. 2004). Phosphorylation motif mutants of SMAD2 and SMAD3 cannot be activated by the TGF-beta receptor complex either because serine residues are substituted with amino acid residues that cannot be phosphorylated or because the phosphorylation motif is deleted from the protein sequence or truncated (Fleming et al. 2013).</Comment>
    <BiopaxRef>bb8</BiopaxRef>
    <BiopaxRef>d1d</BiopaxRef>
    <BiopaxRef>bd8</BiopaxRef>
    <BiopaxRef>a7d</BiopaxRef>
    <BiopaxRef>b5f</BiopaxRef>
    <BiopaxRef>f8a</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="175.5" CenterY="113.5" Width="317.0" Height="55.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-3304356" />
  </DataNode>
  <InfoBox CenterX="0.0" CenterY="0.0" />
  <Biopax>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="bb8">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">23139211</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fleming NI, Jorissen RN, Mouradov D, Christie M, Sakthianandeswaren A, Palmieri M, Day F, Li S, Tsui C, Lipton L, Desai J, Jones IT, McLaughlin S, Ward RL, Hawkins NJ, Ruszkiewicz AR, Moore J, Zhu HJ, Mariadason JM, Burgess AW, Busam D, Zhao Q, Strausberg RL, Gibbs P, Sieber OM.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="f8a">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">15350224</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Structural basis of heteromeric smad protein assembly in TGF-beta signaling.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Chacko BM, Qin BY, Tiwari A, Shi G, Lam S, Hayward LJ, De Caestecker M, Lin K.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="b5f">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">11224571</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">The L3 loop and C-terminal phosphorylation jointly define Smad protein trimerization.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Chacko BM, Qin B, Correia JJ, Lam SS, de Caestecker MP, Lin K.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="c0c">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">12183405</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">No effects of Smad2 (madh2) null mutation on malignant progression of intestinal polyps in Apc(delta716) knockout mice.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Takaku K, Wrana JL, Robertson EJ, Taketo MM.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="dc2">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">12384562</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Compound disruption of smad2 accelerates malignant progression of intestinal tumors in apc knockout mice.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Hamamoto T, Beppu H, Okada H, Kawabata M, Kitamura T, Miyazono K, Kato M.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="f50">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">9753318</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Smad3 mutant mice develop metastatic colorectal cancer.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Zhu Y, Richardson JA, Parada LF, Graff JM.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="d1d">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">8980228</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MADR2 is a substrate of the TGFbeta receptor and its phosphorylation is required for nuclear accumulation and signaling.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Macías-Silva M, Abdollah S, Hoodless PA, Pirone R, Attisano L, Wrana JL.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="bd8">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">9311995</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Nakao A, Imamura T, Souchelnytskyi S, Kawabata M, Ishisaki A, Oeda E, Tamaki K, Hanai J, Heldin CH, Miyazono K, ten Dijke P.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a7d">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">9346966</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Souchelnytskyi S, Tamaki K, Engström U, Wernstedt C, ten Dijke P, Heldin CH.</bp:AUTHORS>
    </bp:PublicationXref>
  </Biopax>
</Pathway>

